内皮素受体拮抗剂治疗慢性心力衰竭的研究进展
被引量：1
摘要
1988年日本学者报道了一种新发现的由21个氨基酸组成的肽类物质内皮素(endothelin,ET)[1].内皮素包括ET-1、ET-2和ET-3亚型,其中,ET-1因为可能与心血管疾病的发生发展有关而特别受到重视.
出处
《中国医药导刊》
2003年第4期291-293,共3页
Chinese Journal of Medicinal Guide
参考文献18
-
1Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cell. Nature,1988;322:411 - 415.
-
2Inoue A, Yanagisawa M, Kimura S, et al. The human endothelin family:three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA, 1989;86:2863 - 2867.
-
3Wei CM, Lerman A, Rodeheffer P,J, et al. Endothelin in human congestive heart failure. Circulation, 1994;89:1580- 1586.
-
4Mulder P, Richard V, Derumeaux G, et al. Role of endogenous endothelin in chronic heart failure. Effect of long -term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodelling. Circulation, 1997;96:1976- 1982.
-
5MacCarthy PA, Grocott - Mason R, Prendergast BD, et al. Contrasting inotropic effects of endogenous endothelin in the normal and failing human heart - studies with an intracoronary ETA receptor antagonist. Circulation,2000;101:142- 147.
-
6Ohlstein E, Douglas S. Endothelin - I modulates vascular smooth muscles tructure and vasomotion: implications in cardiovascular pathology. Drug Dev Res, 1993;29:108- 128.
-
7Levin ER. Endothelins. N Engl J Med. 1995;333: 356- 363.
-
8Benigni A, Remuzzi G. Endothelin antagonists. Lancet, 1999; 353:133- 138.
-
9Dupuis J, Stewart DJ, Cernacek P, et al. Human pulmonary circulation is an important site for both clearance and production of endothelin- 1. Ciculation, 1996;94:1578- 1584.
-
10Shimiyama H, Sabbah HN, Borzak S, et al. Short - term hemodynamic effects of endothelin receptor blockade in dogs with chronic heart failure.Circulation, 1996;94:779 - 784.
同被引文献11
-
1Packer M,Califf RM, Konstam MA, et al. Circulation,2002; 106(8) :920-926
-
2Anker SD,Coats AJ. Int J Cardiol,2002;86(2-3) :123-130
-
3Pitt B,Zannad F,Remme WJ,et al. N Engl J Med,1999;341 (10) :709-717
-
4Pitt B,Remme W, Zannad F,et al. N Engl J Med,2003;348 (14): 1309-1321
-
5Cohn JN,Tognoni G. N Engl J Med,2001;345(23): 1667-1675
-
6McMurray JJ. Heart,2001 ;86(1) :97-103
-
7McMurray JJ,Ostergren J, Swedberg K,et al. Lancet,2003 ; 362(9386) :767-771
-
8Pfeffer MA, Mc Murray JJ, Velazquez EJ et al. N Engl J Med,2003 ; 349(20) : 1893- 1906
-
9Pitt B, Poole Wilson PA, Segal R, et al. Lancet, 2000; 355 (9215) :1582-1587
-
10Chavey WE 2nd, Blaum CS,Bleske BE,et al. Am Fam Physician, 2001 ;64(6) : 1045 - 1054
二级引证文献3
-
1赵秀芳,王梅康,司一民.依普利酮治疗老年慢性心力衰竭的疗效观察[J].浙江临床医学,2009,11(2):163-164. 被引量：1
-
2高勇,张红,汪冬梅.曲美他嗪治疗心力衰竭的效果与分析[J].中国伤残医学,2014,22(8):110-111. 被引量：1
-
3李潇琳,徐丹,梁宇.螺内酯治疗充血性心力衰竭的临床观察及护理[J].护理研究（上旬版）,2009,23(S2):12-12.
-
1郭玉珍,刘琼.内皮素在疾病发生中的作用[J].临床军医杂志,2002,30(2):95-96.
-
2张志祥,夏正红,李德芳,郑岚,徐树进,李荣华,陆履佩,赵佩,苏瑞梅,孙启蔚.血浆内皮素放射免疫分析的临床应用——附141例测定结果分析[J].放射免疫学杂志,1994,7(1):38-39. 被引量：7
-
3赵军,白秋江,胡跃民,雷兵团.内皮素受体拮抗剂临床研究进展[J].河北医药,2009,31(10):1242-1243. 被引量：2
-
4杨姗姗,张贝,王裴珮,赵志玲,张文胜,钱广生.HPLC测定ET-26盐酸盐中的有关物质[J].华西药学杂志,2017,32(1):95-98. 被引量：2
-
5王丽萍,张慈心,苗志敏,柳士秀.肺心病患者血浆内皮素-1水平的变化及其临床意义[J].临床荟萃,1994,9(23):1071-1072. 被引量：1
-
6耿波,刘克良.内皮素受体拮抗剂治疗心血管疾病研究进展[J].中国新药杂志,2003,12(11):884-888. 被引量：2
-
7房芳,王金城,温绍君,张维君.内皮素在冠状动脉搭桥术期间的变化及意义[J].中华胸心血管外科杂志,2001,17(3):183-184. 被引量：1
-
8郭影,孙旸,黄繁嫱.妊娠妇女血清中ET含量与正常人的比较[J].现代检验医学杂志,2005,20(2):39-40.
-
9聂英,程德云.内皮素受体拮抗剂治疗肺动脉高压的研究进展[J].国际呼吸杂志,2007,27(24):1899-1902. 被引量：2
-
10魏莉,查金顺.慢性肺心病患者血浆神经肽Y的变化[J].标记免疫分析与临床,2001,8(3):175-176. 被引量：1
